Recursion stock jumps after solid Q4 beat (RXRX:NASDAQ)

Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone payment from partner Roche (RHHBY). For Q4, the Salt Lake City, Utah-based biotech reported $35.5M in ...